A practical reference on dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
One of the increasingly used methods includes the use of LA-ICP-MS. In LA-ICP-MS, a laser beam is focused on a sample surface, causing it to vaporize and form a high-temperature plasma. This plasma is then introduced into an inductively coupled plasma (ICP) source, where further ionization and excitation occur. The resulting ions are then analysed using a mass spectrometer (MS).
== Medical uses == Alendronatec sodium is indicated for the treatment and prevention of osteoporosis in postmenopausal women; the treatment to increase bone mass in men with osteoporosis; the treatment of glucocorticoid-induced osteoporosis; and the treatment of Paget's disease of bone.
=== November === 1 November – Alan Bickers, civil engineer and local government officer, chief executive of Tauranga City Council (1986–1995), president of IPENZ (1991–1992), chair of Transit New Zealand (2000–2004) (born 1945). 2 November – John Walker, plant biochemist (University of Canterbury) (born 1932). 4 November – Robert Taylor, Hall of Fame musician (Dragon) and songwriter ("This Time", "Magic") (born c. 1951). (death announced on this date) 7 November Patrick Brontë, military historian (born 1970). Bruce Malcolm, rower, lawn bowls player, local politician, trade union official and sports administrator, national men's pairs bowls champion (1990), Port Chalmers Borough Councillor (1968–1977), president of New Zealand Watersiders' Union (1982–1995), president of Otago Rugby Football Union (1988), national men's bowls selector (1998–2008) (born 1935). Roger McClay, politician, MP for Taupo (1981–1984) and Waikaremoana (1984–1996), Minister of Youth Affairs (1990–1996), Commissioner for Children (1998–2003) (born 1945). Lee Tamahori, film director (Once Were Warriors, Die Another Day, Along Came a Spider) (born 1950). 8 November – Gary Williams, cricketer (Otago), table tennis player (Bermuda national team), and sports administrator, chair of Table Tennis New Zealand (2015–2018) (born 1953). 9 November Stephen Clarke, information manager and public servant, Chief Archivist (2020–2022) (born 1970). Susan Skerman, artist (born 1928).
=== Deep brain stimulation === Earlier practitioners of deep brain stimulation in the latter half of the 20th century (Delgado, Heath, Hosbuchi. See Hariz et al. for historical review) were limited by the technology available. Heath, in the 1950s, stimulated subcortical areas and made detailed observations of behavioral changes. In the 1950s, Professor Heath reported on subcortical stimulation with precise descriptions of behavioral changes. A new understanding of pain perception was ushered in in 1965, with the Gate Theory of Wall and Melzack, allowing the beginning a gradual move away from destructive surgical treatments such as cutting nerves and towards reversible, modulatory treatments: neuromodulation. Although now considered oversimplified, the theory held that pain transmissions from small nerve fibers can be overridden, or the gate "closed", by competing transmissions along the wider touch nerve fibers. Building on that concept, in 1967, the first dorsal column stimulator for pain control was demonstrated by Dr. Norm Shealy at Western Reserve Medical School, using a design adapted by Tom Mortimer, a graduate student at Case Institute of Technology, from cardiac nerve stimulators by Medtronic, Inc., where he had a professional acquaintance who shared the circuit diagram. In 1973, Hosbuchi reported alleviating the denervation facial pain of anesthesia dolorosa through ongoing electrical stimulation of the somatosensory thalamus, marking the start of the age of deep brain stimulation.
In 1946, Freeman performed this procedure for the first time on a patient, who was subdued before the operation with electroshock treatment. The transorbital lobotomy procedure, which Freeman performed very quickly, sometimes in less than 10 minutes, was used on many patients with relatively minor mental disorders that Freeman believed did not warrant traditional lobotomy surgery, in which the skull itself was opened. A large proportion of such lobotomized patients exhibited reduced tension or agitation. Many also showed other effects, such as apathy, passivity, lack of initiative, poor concentration, and a generally decreased depth and intensity of their emotional response to life. Some died as a result of the procedure. However, those effects were not widely reported in the 1940s, and at that time, the long-term effects were largely unknown. Because the procedure met with seemingly widespread success, Moniz was awarded the 1949 Nobel Prize for Physiology or Medicine (along with Swiss physiologist Walter Rudolf Hess). Lobotomies were performed on a wide scale during the 1940s; Freeman himself performed or supervised more than 3,500 lobotomies by the late 1960s. Freeman performed his first transorbital lobotomy on Ellen Ionesco, a woman who suffered from bouts of manic depression and suicidal ideation. Freeman utilized media coverage and penned editorials for numerous interviews promoting the procedure and achieving accolades for his work in psychiatric care.
Sources: en.wikipedia.org
=== Diagnostic Nerve Root Block === A highly targeted Diagnostic Nerve Root Block (DNRB) using local anesthetic (eg, 1 cc of 0.25% bupivacaine) can be used as a diagnostic test to determine if a Tarlov cyst is symptomatic.
=== Phase 2 === AGX-201 (histamine dihydrochloride salt) – histamine H1 receptor antagonist and histamine H3 receptor agonist – migraine [7] BHV-2100 – transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonist – migraine [8] Botulinum toxin A longer acting (IPN-10200; mrBoNT) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [9] CAM-01 (C-AM-01) – undefined mechanism of action – migraine [10] Dihydroergotamine mesilate (DFN-19) – non-selective monoamine receptor modulator and ergoline – migraine [11] Doxepin intranasal (Dolorac) – tricyclic antidepressant (non-selective monoamine reuptake inhibitor and receptor modulator and other actions) – headache [12] Elismetrep (K-304; MT-8554) – transient receptor potential cation channel subfamily M member 8 (TRPM8) antagonist – migraine [13] Erenumab (Aimovig; AMG-334) – monoclonal antibody against calcitonin gene-related peptide receptor (CGRPR) – headache [14] Eslicarbazepine acetate (Aptiom; BIA 2-093; ESL; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix) – sodium channel blocker – migraine [15] IONIS-PKKRx (ISIS-546254; ISIS-PKKRx) – antisense oligonucleotide against kallikrein – migraine [16] Ketoprofen topical (ELS-M11; Topofen) – COX inhibitor/NSAID – migraine [17] LAT-8881 (AOD9604; Tyr-hGH171191) – human growth hormone protein fragment and lanthionine synthetase C-like protein (LanCL) ligand – migraine [18] LU-AG09222 (ALD-1910) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP) – migraine [19] LY-3451838 (PACAP-38 antibody) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP) – migraine [20] Lysergic acid diethylamide (LSD; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – cluster headache [21] MTX-101 – undefined mechanism of action – migraine [22] Pasireotide (Signifor; SOM-230) – somatostatin receptor agonist – cluster headache [23] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [24] Sepranolone (isoallopregnanolone; UC-1010) – GABAA receptor negative allosteric modulator and neurosteroid – menstrual migraine [25] TRV-250 – δ-opioid receptor (DOR) agonist – migraine [26] (R)-Verapamil – calcium channel blocker and other actions – cluster headache [27] Zelminemab (AMG-301) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R) – migraine [28]
The production of thyroxine and triiodothyronine is primarily regulated by thyroid-stimulating hormone (TSH), released by the anterior pituitary gland. TSH release in turn is stimulated by thyrotropin releasing hormone (TRH), released in a pulsatile manner from the hypothalamus. The thyroid hormones provide negative feedback to the thyrotropes TSH and TRH: when the thyroid hormones are high, TSH production is suppressed. This negative feedback also occurs when levels of TSH are high, causing TRH production to be suppressed. TRH is secreted at an increased rate in situations such as cold exposure in order to stimulate thermogenesis. In addition to being suppressed by the presence of thyroid hormones, TSH production is blunted by dopamine, somatostatin, and glucocorticoids.
Boosted considerably by the arrival of three South African brigades during the last months of 1940, the Commonwealth forces in Kenya had expanded to three divisions by the end of the year. No. 237 Squadron was relieved by South African airmen and redeployed to the Sudan in September. Rebasing at Khartoum, No. 237 Squadron undertook regular reconnaissance, dive-bombing and strafing sorties during October and November 1940. Meanwhile, the Southern Rhodesian Anti-Tank Battery arrived in Kenya in October and, following a period of training, received 2-pounder guns and joined the front at Garissa around the turn of the new year. No. 237 Squadron was partially re-equipped during January 1941, receiving some Westland Lysander Mk IIs, but most of the squadron continued operating Hardys. The British forces in Kenya under General Alan Cunningham, including Rhodesian officers and NCOs in the King's African Rifles and the Nigeria and Gold Coast Regiments, as well as the South African 1st South African Infantry Division, advanced into Abyssinia and Italian Somaliland during late January and February 1941, starting with the occupation of the ports of Kismayo and Mogadishu. The Italians retreated to the interior. No. 237 Squadron meanwhile provided air support to the 4th Indian Infantry Division and 5th Indian Infantry Division during Lieutenant-General William Platt's offensive into Eritrea from the Sudan, attacking ground targets and engaging Italian fighters. One of the Rhodesian Hardys was shot down near Keren on 7 February with the loss of both occupants.
Sources: en.wikipedia.org
==== Countercurrent flow examples ==== In a countercurrent heat exchanger, the hot fluid becomes cold, and the cold fluid becomes hot. In this example, hot water at 60 °C (140 °F) enters the top pipe. It warms water in the bottom pipe which has been warmed up along the way, to almost 60 °C (140 °F). A minute but existing heat difference still exists, and a small amount of heat is transferred, so that the water leaving the bottom pipe is at close to 60 °C (140 °F). Because the hot input is at its maximum temperature of 60 °C (140 °F), and the exiting water at the bottom pipe is nearly at that temperature but not quite, the water in the top pipe can warm the one in the bottom pipe to nearly its own temperature. At the cold end—the water exit from the top pipe, because the cold water entering the bottom pipe is still cold at 20 °C (68 °F), it can extract the last of the heat from the now-cooled hot water in the top pipe, bringing its temperature down nearly to the level of the cold input fluid (21 °C (70 °F)). The result is that the top pipe which received hot water, now has cold water leaving it at 20 °C (68 °F), while the bottom pipe which received cold water, is now emitting hot water at close to 60 °C (140 °F). In effect, most of the heat was transferred.
The cations of these strong bases appear in the first and second groups of the periodic table (alkali and earth alkali metals). Tetraalkylated ammonium hydroxides are also strong bases since they dissociate completely in water. Guanidine is a special case of a species that is exceptionally stable when protonated, analogously to the reason that makes perchloric acid and sulfuric acid very strong acids.
"A Fighter From the Ground Up." Popular Science, July 1943, one of earliest detailed articles on P-51A Archived 23 October 2013 at the Wayback Machine "Wild Horses of the Sky," Popular Mechanics, November 1943 Joe Baugher, North American P-51 Mustang Archived 23 July 2011 at the Wayback Machine Camouflage and Markings of P-51 Mustang Parts 1–4 USAAF plus Allison engine versions RAF and Commonwealth Archived 1 March 2012 at the Wayback Machine Allison-powered Mustang performance test reports; 1940, 1942, 1943, 1944 Archived 22 December 2008 at the Wayback Machine P-51B Mustang performance test report, May 1943 Archived 9 January 2008 at the Wayback Machine P-51 combat reports Archived 23 December 2007 at the Wayback Machine NACA-WR-L-566 "Flying qualities and stalling characteristics of North American XP-51 airplane", April 1943. (PDF) North American P-51 profile, photos and technical details for each mk "Flight Characteristics of the North American P-51 Mustang: How to Fly the P-51 Mustang" on YouTube "Mustang Squadron" a 1942 Flight article "Army Co-Op Mustang" a 1942 Flight article "Unobtrusive Cleverness" a 1942 Flight article "Long Range Mustang" a 1944 Flight article P-51 in Flight Over California (1942) Flight manual Mustang P-51A Archived 15 May 2024 at the Wayback Machine – The Museum of Flight Digital Collections Pilot training manual for the Mustang P-51 Archived 8 October 2024 at the Wayback Machine – The Museum of Flight Digital Collections
==== Spirituality ==== While religion is often formalised and community-oriented, spirituality tends to be individually based and not as formalised. In a 2014 study, 320 children, ages 8–12, in both public and private schools, were given a Spiritual Well-Being Questionnaire assessing the correlation between spirituality and happiness. Spirituality – and not religious practices (praying, attending church services) – correlated positively with the child's happiness; the more spiritual the child was, the happier the child was. Spirituality accounted for about 3–26% of the variance in happiness. Meditation has been found to lead to high activity in the brain's left prefrontal cortex, which in turn has been found to correlate with happiness. A study using the Oxford happiness questionnaire on Brahma Kumaris Raja yoga meditators showed them having higher happiness than the control group. Yongey Mingyur Rinpoche has said that neuro scientists have found that with meditation, an individual's happiness baseline can change. Many people describe themselves as both religious and spiritual, but spirituality represents just one particular function of religion. Spirituality as related to positive psychology can be defined as "a search for the sacred". What is defined as sacred can be related to God, life itself, or almost any other facet of existence. It is viewed as having spiritual implications which are transcendent of the individual. Spiritual well-being addresses this human need for transcendence and involves social as well as existential well-being.
=== 21st century === In the past decade, documenting forensics scenes has become more efficient. Forensic scientists have started using laser scanners, drones and photogrammetry to obtain 3D point clouds of accidents or crime scenes. Reconstruction of an accident scene on a highway using drones involves data acquisition time of only 10–20 minutes and can be performed without shutting down traffic. The results are not just accurate, in centimeters, for measurement to be presented in court but also easy to digitally preserve in the long term. Now, in the 21st century, much of forensic science's future is up for discussion. The National Institute of Standards and Technology (NIST) has several forensic science-related programs: CSAFE, a NIST Center of Excellence in Forensic Science, the National Commission on Forensic Science (now concluded), and administration of the Organization of Scientific Area Committees for Forensic Science (OSAC). One of the more recent additions by NIST is a document called NISTIR-7941, titled "Forensic Science Laboratories: Handbook for Facility Planning, Design, Construction, and Relocation". The handbook provides a clear blueprint for approaching forensic science. The details even include what type of staff should be hired for certain positions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.